|
 "Just because we now have a new CEO, you shouldn't expect large
acquisitions to be taken on at any cost. We are absolutely open for
it and very ready but every transaction has to stand on its own
feet, make strategic sense and furthermore pay off. From a position
of strength we can very carefully observe any opportunities that
emerge," CEO Stephan Sturm told journalists in a conference call to
discuss second-quarter results on Tuesday.
Sources told Reuters in June Fresenius placed a bid for U.S.
drugmaker Pfizer's infusion pumps business in a possible deal worth
close to $1.5 billion but no agreement has emerged since.
Sturm said on Tuesday Fresenius was launching a new product to
tackle its relatively weak position in the U.S. infusion-pump market
compared with other regions but added takeovers should not be ruled
out to address the issue.
(Reporting by Ludwig Burger; Editing by Maria Sheahan)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
